Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients

Journal of Medical Virology

Volumn 83, Issue 1, 2011, Pages 88-94

  Song, Eun Young ^a   Shin, Yunsu ^a   Roh, Eun Youn ^a   Sue, Shin ^a   Park, Myoung Hee ^a   Kim, Bo Hyun ^b   Kim, Won ^c   Yoon, Jung Hwan ^a   Lee, Youn Jae ^d   Park, Sung Jae ^d   Jung, Eun Uk ^d   Lee, Jeong Hoon ^a   Myung, Sun Jung ^a   Kim, Yoon Jun ^a   Lee, Hyo Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Bundang Jesaeng Hospital   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d Inje University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; HBeAg seroconversion; HBsAg quantitation; Hepatitis B virus (HBV) DNA; Peginterferon

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; THYMOSIN ALPHA1; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTIVE VALIDITY; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; DNA, VIRAL; DRUG MONITORING; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; SERUM; THYMOSIN; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 78649559595     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21961     Document Type: Article

References (28)

1. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. 2009. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49: 1141-1150.
2. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. 2007. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 5: 1462-1468.
3. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, Iinuma K, Mushahwar IK. 2004. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Method 115: 217-222.
4. European Association for the Study of the Liver. 2009. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 50: 227-242.
5. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M. 2008. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47: 428-434.
6. Guan R. 2005. Treatment of chronic hepatitis B infection using interferon. Med J Malaysia 60: 28-33.
7. Heijtink RA, Janssen HL, Hop WC, Osterhaus AD, Schalm SW. 2000. Interferon-alpha therapy in chronic hepatitis B: Early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 7: 382-386.
8. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. 1981. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 94: 744-748.
9. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. 2007. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 45: 1056-1075.
10. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 365: 123-129.
11. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, Flisiak R, Bock CT, Manns MP, Wedemeyer H, Cornberg M. 2010. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. J Hepatol 52: 514-522.
12. Kao JH. 2002. Hepatitis B viral genotypes: Clinical relevance and molecular characteristics. J Gastroenterol Hepatol 17: 643-650.
13. Kim H, Jee YM, Song BC, Shin JW, Yang SH, Mun HS, Kim HJ, Oh EJ, Yoon JH, Kim YJ, Lee HS, Hwang ES, Cha CY, Kook YH, Kim BJ. 2007. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 50: 52-57.
14. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, Sakaguchi H, Seki S, Shiomi S, Nishiguchi S. 2005. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 75: 235-239.
15. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354: 1011-1020.
16. Lau GK, Marcellin P, Brunetto M, Piratvisuth T, Kapprell HP, Button P, Batrla R. 2008. On-treatment HBsAg decline during peginterferon alfa-2a (40kD)±lamivudine in patients with HBeAg-positive CHB as a potential predictors of durable off-treatment response. Hepatology 48: 714A.
17. Lok AS, McMahon BJ. 2004. Chronic hepatitis B: Update of recommendations. Hepatology 39: 857-861.
18. Lok AS, McMahon BJ. 2007. Chronic hepatitis B. Hepatology 45: 507-539.
19. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. 2007. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: A clue from serum level of HBsAg. Antivir Ther 12: 73-82.
20. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. 2009. Early serum HBsAg drop: A strong predictor of sustained virologic response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49: 1151-1157.
21. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA. 2010. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia. J Hepatol 52: 508-513.
22. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D. 1996. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334: 1422-1427.
23. Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, Senturk H. 2008. Correlation of quantitative assay of HBsAg and level of HBV DNA during chronic HBV treatment. Dig Dis Sci 53: 2995-2998.
24. Realdi G, Alberti A, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, Ruol A. 1980. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 79: 195-199.
25. Song BC, Cui XJ, Kim H. 2005. Hepatitis B virus genotypes in Korea: An endemic area of hepatitis B virus infection. Intervirology 48: 133-137.
26. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA. 2010. Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51: 1933-1944.
27. Wiegand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, Michel G, Bock CT, Manns MP, Tillmann HL. 2008. A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or level of HBV DNA. Antivir Ther 13: 547-554.
28. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119: 312-323.